0001752724-19-161454.txt : 20191114
0001752724-19-161454.hdr.sgml : 20191114
20191113194318
ACCESSION NUMBER: 0001752724-19-161454
CONFORMED SUBMISSION TYPE: N-CEN
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20190831
FILED AS OF DATE: 20191114
DATE AS OF CHANGE: 20191113
EFFECTIVENESS DATE: 20191114
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: UBS INVESTMENT TRUST
CENTRAL INDEX KEY: 0000873803
IRS NUMBER: 000000000
STATE OF INCORPORATION: MA
FISCAL YEAR END: 0831
FILING VALUES:
FORM TYPE: N-CEN
SEC ACT: 1940 Act
SEC FILE NUMBER: 811-06292
FILM NUMBER: 191215860
BUSINESS ADDRESS:
STREET 1: C/O UBS ASSET MANAGEMENT (AMERICAS) INC.
STREET 2: 12TH FLOOR 1285 AVENUE OF THE AMERICAS
CITY: NEW YORK
STATE: NY
ZIP: 10019
BUSINESS PHONE: 212-821-3000
MAIL ADDRESS:
STREET 1: C/O UBS ASSET MANAGEMENT (AMERICAS) INC.
STREET 2: 12TH FLOOR 1285 AVENUE OF THE AMERICAS
CITY: NEW YORK
STATE: NY
ZIP: 10019
FORMER COMPANY:
FORMER CONFORMED NAME: BRINSON INVESTMENT TRUST
DATE OF NAME CHANGE: 20010625
FORMER COMPANY:
FORMER CONFORMED NAME: PAINEWEBBER INVESTMENT TRUST
DATE OF NAME CHANGE: 19960511
FORMER COMPANY:
FORMER CONFORMED NAME: KIDDER PEABODY INVESTMENT TRUST
DATE OF NAME CHANGE: 19920929
0000873803
S000002487
UBS U.S. Allocation Fund
C000006689
Class A
PWTAX
C000006692
Class P
PWTYX
N-CEN
1
primary_doc.xml
X0201
N-CEN
LIVE
0000873803
XXXXXXXX
811-06292
false
false
false
N-1A
S000002487
C000006689
C000006692
UBS INVESTMENT TRUST
811-06292
0000873803
549300G2BM6HG0OCX065
C/O UBS ASSET MANAGEMENT (AMERICAS) INC.
12TH FLOOR 1285 AVENUE OF THE AMERICAS
NEW YORK
10019
US-NY
US
212-821-3000
State Street Bank and Trust Company
1 Lincoln Street
Boston
02111
617-786-3000
Custody and Accounting Records.
N
N
N-1A
1
Y
Alan S. Bernikow
000000000
N
Heather R. Higgins
000000000
N
Meyer Feldberg
000000000
Y
Bernard H. Garil
000000000
N
Richard R. Burt
000000000
N
Frank Pluchino
001499081
787 Seventh Avenue
New York
10019
XXXXXX
N
N
N
N
N
N
N
UBS Asset Management (US) Inc.
8-21901
000000583
0000000000
Y
N
Ernst & Young LLP
42
00000000000000000000
N
N
N
N
N
N
N
UBS U.S. Allocation Fund
S000002487
549300J5GDB8VRARXP29
N
2
0
1
N/A
N
N
Y
N
N
State Street Bank and Trust Company
571474TGEMMWANRLN572
N
N
Revenue sharing split
Cash collateral reinvestment fee
4442425.59000000
10653.00000000
Rule 22d-1 (17 CFR 270.22d-1)
Rule 32a-4 (17 CFR 270.32a-4)
Rule 12d1-1 (17 CFR 270.12d1-1)
Rule 17a-7 (17 CFR 270.17a-7)
Rule 10f-3 (17 CFR 270.10f-3)
Y
N
Y
N
UBS Asset Management (Americas) Inc.
801-34910
000106838
F88SLSBEMHN5FUSNRO91
N
BNY Mellon Investment Servicing (US) Inc.
084-01761
549300CFZQLI9QMJ1Z03
N
N
N
Standard & Poor's Financial Services LLC
549300U4VWNITEKO2881
N
Bloomberg L.P.
549300B56MD0ZC402L06
N
PricingDirect Inc.
549300WIC0TOJ7N7GD54
N
IHS Markit Ltd.
549300HLPTRASHS0E726
GB
N
ICE Data Services, Inc.
13-3668779
Tax ID
N
Refinitiv US Holdings Inc.
549300NF240HXJO7N016
N
N
State Street Bank and Trust Company
571474TGEMMWANRLN572
N
N
Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1))
Euroclear Limited
54930045L3MXWBD27H71
CH
N
Y
Foreign securities depository - rule 17f-7 (17 CFR 270.17f-7)
N
BNY Mellon Investment Servicing (US) Inc.
549300CFZQLI9QMJ1Z03
N
N
N
UBS Asset Management (Americas) Inc.
F88SLSBEMHN5FUSNRO91
Y
N
N
UBS Securities Pte. Ltd. (Jung-gu, Seoul, KR, Branch)
N/A
000000000
5493003VITE2RS406E89
KR
0.00000000
UBS Securities India Private Limited
N/A
000000000
549300TVEJCTJLRAKC65
IN
0.00000000
UBS Securities LLC
8-22651
000007654
T6FIZBDPKLYJKFCRVK44
0.00000000
UBS Financial Services Inc.
8-16267
000008174
ETYRV6ORNFJB5NONI676
0.00000000
UBS Securities Asia Limited
N/A
000000000
549300Y35FCB6270R069
HK
0.00000000
UBS AG
N/A
000000000
BFM8T61CT2L1QCEMIK50
CH
0.00000000
UBS Securities Pte. Ltd.
N/A
000000000
549300OODOO0QOU3BT85
SG
0.00000000
UBS Limited
N/A
000000000
REYPIEJN7XZHSUI0N355
GB
0.00000000
Morgan Stanley & Co. LLC
8-15869
000008209
9R7GPTSO7KV3UQJZQ078
6506.97000000
JPMorgan Chase & Co.
8-35008
000000079
8I5DZWZKVSZI1NUHU748
4250.77000000
Merrill Lynch, Pierce, Fenner & Smith Incorporated
8-7221
000007691
8NAV47T0Y26Q87Y0QP81
12620.80000000
Pershing LLC
8-17574
000007560
ZI8Q1A8EI8LQFJNM0D94
14133.76000000
Goldman Sachs & Co. LLC
8-129
000000361
FOR8UP27PHTHYVLBNG30
4723.00000000
Cowen and Company, LLC
8-22522
000007616
549300WR155U7DVMIW58
2762.70000000
Credit Suisse Securities (USA) LLC
8-422
000000816
1V8Y6QCX6YMJ2OELII46
3081.09000000
Citigroup Global Markets Inc.
8-8177
000007059
MBNUM2BPBDO7JBLYG310
2839.28000000
Jefferies LLC
8-15074
000002347
58PU97L1C0WSRCWADL48
11217.28000000
Robert W. Baird & Co. Incorporated
8-497
000008158
549300772UJAHRD6LO53
2028.93000000
68515.28000000
Jefferies LLC
8-15074
000002347
58PU97L1C0WSRCWADL48
6695696.28000000
Credit Suisse Securities (USA) LLC
8-422
000000816
1V8Y6QCX6YMJ2OELII46
13515007.24000000
JPMorgan Chase & Co.
8-35008
000000079
8I5DZWZKVSZI1NUHU748
23080189.20000000
The Bank of New York Mellon
8-35255
000017454
HPFHU0OQ28E4N0NFVK49
19351883.59000000
Citigroup Global Markets Inc.
8-8177
000007059
MBNUM2BPBDO7JBLYG310
179547060.16000000
Barclays Capital Inc.
8-41342
000019714
AC28XWWI3WIBK2824319
42075348.13000000
Merrill Lynch, Pierce, Fenner & Smith Incorporated
8-7221
000007691
8NAV47T0Y26Q87Y0QP81
72210980.26000000
Morgan Stanley & Co. LLC
8-15869
000008209
9R7GPTSO7KV3UQJZQ078
52045122.15000000
Goldman Sachs & Co. LLC
8-129
000000361
FOR8UP27PHTHYVLBNG30
44066531.20000000
Wells Fargo Securities, LLC
8-65876
000126292
VYVVCKR63DVZZN70PB21
16711454.18000000
491185523.71000000
N
235751767.71000000
Committed
185000000.00000000
N
N
N
N
true
INTERNAL CONTROL RPT
2
NCEN_15410234166926384.txt
Report of Independent Registered Public Accounting
Firm
To The Board of Trustees and Shareholders of UBS Investment
Trust
In planning and performing our audit of the financial statements
of UBS U.S. Allocation Fund (the sole fund
constituting UBS Investment Trust) (the "Company") as of and
for the period ended August 31, 2019, in
accordance with the standards of the Public Company Accounting
Oversight Board (United States), we
considered the Company's internal control over financial
reporting, including controls over safeguarding
securities, as a basis for designing our auditing procedures for the
purpose of expressing our opinion on the
financial statements and to comply with the requirements of Form
N-CEN, but not for the purpose of expressing
an opinion on the effectiveness of the Company's internal control
over financial reporting. Accordingly, we
express no such opinion.
The management of the Company is responsible for establishing
and maintaining effective internal control over
financial reporting. In fulfilling this responsibility, estimates and
judgments by management are required to
assess the expected benefits and related costs of controls. A
company's internal control over financial reporting is
a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the
preparation of financial statements for external purposes in
accordance with U.S. generally accepted accounting
principles. A company's internal control over financial reporting
includes those policies and procedures that (1)
pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and
dispositions of the assets of the company; (2) provide reasonable
assurance that transactions are recorded as
necessary to permit preparation of financial statements in
accordance with U.S. generally accepted accounting
principles, and that receipts and expenditures of the company are
being made only in accordance with
authorizations of management and trustees of the company; and
(3) provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use or
disposition of a company's assets that could
have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial
reporting may not prevent or detect
misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in
conditions, or that the degree of compliance with the
policies or procedures may deteriorate.
A deficiency in internal control over financial reporting exists
when the design or operation of a control does not
allow management or employees, in the normal course of
performing their assigned functions, to prevent or
detect misstatements on a timely basis. A material weakness is a
deficiency, or combination of deficiencies, in
internal control over financial reporting, such that there is a
reasonable possibility that a material misstatement of
the company's annual or interim financial statements will not be
prevented or detected on a timely basis.
Our consideration of the Company's internal control over
financial reporting was for the limited purpose
described in the first paragraph and would not necessarily
disclose all deficiencies in internal control that might
be material weaknesses under standards established by the Public
Company Accounting Oversight Board (United
States). However, we noted no deficiencies in the Company's
internal control over financial reporting and its
operation, including controls over safeguarding securities that we
consider to be a material weakness as defined
above as of August 31, 2019.
This report is intended solely for the information and use of
management and the Board of Trustees of UBS
Investment Trust and the Securities and Exchange Commission
and is not intended to be and should not be used
by anyone other than these specified parties.
/s/ ERNST & YOUNG LLP
New York, New York
October 28, 2019